The eventual progression of HR-positive breast cancer, even after treatment with CDK4/6 inhibitors, has limited the success of this therapy in the clinic, emphasizing the need to identify mechanisms of this acquired resistance. This evidence concerns the gene CDK4 and breast carcinoma.